D9099-43
CAS Number
23214-92-8Grade
Highly PurifiedMolecular Formula
C27H29NO11Molecular Weight
543.52EU Commodity Code
38220090Shipping Temp
Blue IceStorage Temp
-20°CDoxorubicin (Adriamycin, 14-Hydroxydaunomycin)
Adriamycin; Hydroxydaunorubicin; DOX; 14-Hydroxydaunomycin
Doxorubicin is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumor agent for the treatment of a wide range of cancers. Doxorubicin has also been reported to exhibit anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.
Molecular Formula
C27H29NO11
Apperance
Orange-red solid
Solubility (100mg/ml)
Soluble in DMSO and water
Method of Determing Identity
NMR Spectrometric Analysis
Storage and Stability
Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Light Sensitive.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards
All products should be handled by qualified personnel only, trained in laboratory procedures.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
US Biological application references: Abouzeid, A.H., et al., (2013) J Drug Target., doi:10.3109/1061186X.2013.840639. |General references: 1. Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Arcamone F. et al., Tet. Letters 1969, 13, 1007. 2. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Fornari F.L. et al., Mol. Pharmacology 1994, 45, 649. 3. Effect of Adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Momarier R. et al., Cancer Research 1976, 36, 2891.USBio References
US Biological application reference: Abouzeid, A.H., et al., (2013) J Drug Target., doi:10.3109/1061186X.2013.840639.